In patients with triple-negative disease (estrogen receptor (ER) negative, progesterone receptor (PR) negative, and HER2 negative), the cancer is presumably an aggressive subtype, and thus first-line chemotherapy is recommended. This evidence concerns the gene PGR and cancer.